migraine
FDA grants De Novo authorisation to light-filtering device for migraine
August 28, 2026De Novo, FDA, light-filtering device, migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, a precision optical filter designed …
Teva’s Ajovy significantly reduces migraine in children and adolescents
January 12, 2026Research and Development Neurology, Teva, ajovy, migraine
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children and adolescents with episodic migraine …
Teva announces positive results from trial of AJOVY for migraine
December 5, 2025Research and Development Neurology, Teva, migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and …
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
July 1, 2025Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …
NICE recommends migraine treatment for NHS use
April 11, 2024Medical Communications NHS, NICE, Neurology, migraine
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …
American Heart Association awards $2.1m to research link between migraine, strokes and CVD
July 27, 2023Research and Development American Heart Association, Cardiology, cvd, migraine, stroke
The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …
NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks
June 2, 2023Medical Communications NHS, NICE, Neurology, Pfizer, migraine
The National Institute for Health and Care Excellence (NICE) has announced that it has recommended an oral treatment for the …
New study challenges link between stress and migraines
January 25, 2021Sales and Marketing Curelator, migraine
Digital health platform Curelator has announced new data that shows a lack of association between increased stress and migraine attacks. …
NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine
December 11, 2020Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine
NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …
Axsome’s late-stage study of experimental depression drug misses main trial goal
March 31, 2020Manufacturing and Production Depressive Disorder, MDD, depression, migraine
Axsome Therapeutics reported on Monday that its Phase 3 study of its experimental depression drug missed its main trial goal. …
Teva’s Ajovy becomes first drug of its kind available on NHS for prevention of chronic migraine
March 12, 2020Sales and Marketing NICE, Teva, ajovy, migraine, pharma
NICE has announced the authorisation of Teva’s anti-CGRP drug Ajovy (fremanezumab) for the prevention of chronic migraine in adult patients …
Lundbeck’s Vyepti secures US approval for migraine prevention
February 24, 2020Sales and Marketing FDA, Lundbeck, Vyepti, migraine, pharma
Lundbeck’s Vyepti (eptinezumab-jjmr) has secured approval from the FDA, it has emerged, for the prevention of migraine in adult patients. …
FDA approves Teva’s Ajovy autoinjector for treatment of migraine
January 29, 2020Research and Development, Sales and Marketing FDA, Teva, ajovy, migraine, pharma
Israeli pharma firm Teva has revealed that the FDA has chosen to award approval to its autoinjector device for the …
Lilly’s Reyvow becomes first FDA-approved 5-HT1F receptor agonist for acute migraine
October 15, 2019Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Reyvow, US, migraine, pharma
Eli Lilly has announced that the FDA has given the green light to Reyvow (lasmiditan) in the acute treatment of …
NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland
September 26, 2019Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma
NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
